Vertex to Acquire Semma Therapeutics for Developing Curative Cell-Based Therapies to Treat Type 1 Diabetes

 Vertex to Acquire Semma Therapeutics for Developing Curative Cell-Based Therapies to Treat Type 1 Diabetes

Vertex to Acquire Semma Therapeutics for Developing Curative Cell-Based Therapies to Treat Type 1 Diabetes

Shots:

  • Vertex acquires Semma Therapeutics, in all cash transaction making a total deal value $950M and Semma will operate as a subsidiary of Vertex. The transaction is expected to be completed in Q4’19
  • The acquisition targets Semma’s unique investigational approach of combining the production of Islets of Langerhans cells in the pancreas with a delivery system to restore insulin secretion in T1D patients
  • Islet cell transplantation provides physiologic regulation of blood glucose, thus prevent both hyperglycemic and hypoglycemic episodes associated with the current SOC i.e, insulin injection & pumps

Click here to­ read full press release/ article | Ref: Vertex | Image: Odessa American

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post